{
    "clinical_study": {
        "@rank": "166619", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (auranofin)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive auranofin PO on day 2."
            }, 
            {
                "arm_group_label": "Arm II (placebo)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive placebo PO on day 2."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized pilot trial studies whether auranofin will relieve pain following\n      paclitaxel in patients who have previously experienced paclitaxel-induced pain. Auranofin is\n      a drug given by mouth to treat other diseases such as rheumatoid arthritis, and is being\n      studied to see if it will decrease pain following paclitaxel."
        }, 
        "brief_title": "Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome", 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Determine whether one dose of auranofin given the day following administration of\n      paclitaxel decreases pain as assessed by daily completion of the Modified Brief Pain\n      Inventory scale for seven days.\n\n      SECONDARY OBJECTIVES:\n\n      I. Assess whether auranofin is well tolerated in this setting.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients receive auranofin orally (PO) on day 2.\n\n      ARM II: Patients receive placebo PO on day 2.\n\n      After completion of study treatment, patients are followed up 21-28 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Absolute neutrophil count (ANC) >= 1500/mm^3\n\n          -  Platelet count (PLT) >= 100,000/mm^3\n\n          -  Creatinine =< 2 x upper limit of normal (ULN)\n\n          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) and\n             serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =<\n             1.5 x ULN\n\n          -  Total/direct bilirubin =< 1.5 x ULN\n\n          -  Alkaline phosphatase =< 1.5 x ULN\n\n          -  Hemoglobin >= 9 mg/dL\n\n          -  Negative urine or serum pregnancy test performed =< 7 days prior to registration, for\n             women of childbearing potential only\n\n          -  Previously experienced paclitaxel induced pain during a current or past paclitaxel\n             treatment that the treating healthcare provider thinks is consistent with the\n             paclitaxel-induced acute pain syndrome; note: formal documentation of prior pain is\n             not required\n\n          -  Scheduled to receive paclitaxel at a dose >= 70 mg/m^2 =< 14 days from randomization\n\n          -  Ability to complete the questionnaires or to do so with assistance\n\n        Exclusion Criteria:\n\n          -  Pregnant women\n\n          -  Nursing women\n\n          -  Any woman of childbearing potential or male partner of a woman of childbearing\n             potential unwilling to employ acceptable contraception throughout the study and for\n             at least 30 days after the last dose of the study drug\n\n          -  History of gold-induced disorders, including but not limited to, necrotizing\n             enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasias or\n             other severe hematologic disorders; history of severe allergic or anaphylactic\n             reactions or hypersensitivity to auranofin or other gold compounds\n\n          -  Currently receiving Dilantin (phenytoin) or auranofin or another gold-containing\n             compound\n\n          -  Anticipated use of filgrastim (G-CSF) or sargramostim (GM-CSF) within 30 days after\n             receiving auranofin\n\n          -  Currently receiving immune-modulating therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063698", 
            "org_study_id": "MC1364", 
            "secondary_id": [
                "NCI-2014-00165", 
                "MC1364", 
                "P30CA015083"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (auranofin)", 
                "description": "Given PO", 
                "intervention_name": "auranofin", 
                "intervention_type": "Drug", 
                "other_name": "Ridaura"
            }, 
            {
                "arm_group_label": "Arm II (placebo)", 
                "description": "Given PO", 
                "intervention_name": "placebo", 
                "intervention_type": "Other", 
                "other_name": "PLCB"
            }, 
            {
                "arm_group_label": [
                    "Arm I (auranofin)", 
                    "Arm II (placebo)"
                ], 
                "description": "Ancillary studies", 
                "intervention_name": "questionnaire administration", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Auranofin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "contact": {
                "email": "jatoi.aminah@mayo.edu", 
                "last_name": "Aminah Jatoi", 
                "phone": "507-284-2511"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": {
                "last_name": "Aminah Jatoi", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Randomized, Placebo-Controlled Study to Test Auranofin (Ridaura\u00ae) to Control the Paclitaxel-Induced Pain Syndrome (PIAPS)", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Aminah Jatoi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The per arm percentage of patients who report having experienced the PIAPS for one week after paclitaxel after enrollment to the current trial will be assessed based on the response to the question \"Please rate your pain by circling the one number that best describes your pain at its worst in the last 24 hours\". The area under the curves based on whether patients were assigned to the intervention arm versus placebo arm will be compared using two-sample t-tests.", 
                "measure": "Percentage of patients who report having experienced the paclitaxel-induced pain syndrome (PIAPS) for one week after paclitaxel after enrollment to the current trial, assessed by the Modified Brief Pain Inventory Scale (BPI)", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "description": "The proportion of patients who rate their pain as >= 4 will be summarized and compared using summary statistics and chi-square test. Average scores for this question will also be compared using two-sample t-tests.", 
                "measure": "Proportion of patients who rate their pain as >= 4 assessed by the BPI", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063698"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "An area under the curve for other pain items on the modified BPI will be constructed and compared based on whether patients were assigned to the intervention arm versus the placebo arm using two-sample t-tests or a non-parametric test as appropriate.", 
                "measure": "Area under the curve for other pain items on the modified BPI", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "description": "Compared using summary statistics.", 
                "measure": "Locations of pain", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "description": "The average responses for these questions from the modified BPI using a two-sample t-test methodology or non-parametric test as appropriate.", 
                "measure": "Average responses to questions from the modified BPI", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "description": "Adverse events will be captured using summary statistics and frequencies of adverse events will be compared using chi-square tests.", 
                "measure": "Incidence of adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "description": "Pain descriptors and locations will be compared using summary statistics.", 
                "measure": "Pain descriptions and locations as measured by the PIAPS Symptom Summary", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}